Shares of AstraZeneca and Daiichi Sankyo tumbled after the pair’s lung cancer drug showed mixed results in a late-stage trial. Speaking exclusively to Bloomberg, AstraZeneca CEO Pascal Soriot says the trials were not 'perfect' but won't affect long-term numbers. Soriot also commented on the ongoing probe by Chinese government where several of the drug maker's employees have been detained. He says AstraZeneca has strong compliance policies in China, and is working closely with authorities following the detention of several employees in the country.